Top Industry Leaders in the Nephroblastoma Treatment Market
Latest Nephroblastoma Treatment Companies Updates:
Blueprint Medicines Corporation Received FDA approval for Ayvakit (avapritinib), a targeted therapy for relapsed or refractory Wilms tumor with FGFR3/4 genetic alterations, offering a new treatment option for this aggressive form of the disease.
Janssen Pharmaceuticals Introduced Tecentriq™ (atezolizumab), an immune checkpoint inhibitor, showing promising results in clinical trials for Wilms tumor treatment, potentially leading to improved outcomes.
BlueSphere Therapeutics Developed BBT-870, a novel drug candidate targeting MYCN amplification, a genetic factor associated with aggressive Wilms tumor, currently in early clinical trials.
Pfizer Inc Acquired Mylan N.V., gaining access to Mylan's existing portfolio of oncology drugs, including treatments for Wilms tumor, strengthening its presence in the pediatric oncology market.
Novartis AG Partnered with the Children's Oncology Group (COG) to conduct clinical trials for Wilms tumor treatment, facilitating faster development and evaluation of new drugs for this rare pediatric cancer.
Merck & Co., Inc Collaborated with academic institutions to research and develop novel biomarkers for Wilms tumor risk assessment and treatment response prediction, aiming to personalize therapy strategies.
List of Nephroblastoma Treatment Key companies in the market
-
Bayer HealthCare LLC (U.S.)
-
F. HoffmannLa Roche Ltd (Switzerland)
-
Pfizer Inc. (U.S.),
-
Sanofi Pasteur Inc. (U.S.)
-
Merck & Co. Inc. (U.S.)
-
MediLexicon International Ltd (U.S.),
-
Bristol-Myers Squibb Company (U.S.),